Insulin, Neurogenetics and Memory in Alzheimer's Disease

Completed · Phase 2

Conditions studied: Alzheimer Disease

In brief

This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.

Key facts

Study ID

NCT00018382

Run by

US Department of Veterans Affairs

Starts

1999-10-01

Expected to finish

2003-03-01

Last updated by the study team

2009-01-21

Who can join

Age: 55 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• VA Puget Sound Health Care System — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.